News & Views | Telix Pharmaceuticals Limited

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

Telix today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga (gallium)-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating PET imaging for patient selection for rADC therapy. The Company has previously reported final safety data from this study[3].

Telix Highlights ProstACT GLOBAL and STARLITE-1 Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2024

Telix today announces two abstract presentations featuring the Company’s therapeutic radiopharmaceutical programs at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 31 – June 4, 2024.

Telix Submits NDA for New Prostate Cancer Imaging Agent

Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging for prostate cancer.

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

Telix today announces the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.

Telix Announces Abstract Presentations at BNMS Annual Spring Meeting

Telix today announces three abstract presentations featuring the Company’s theranostic programs at the British Nuclear Medicine Society (BNMS) Annual Spring Meeting being held in Belfast, Northern Ireland this week.

Telix and Cardinal Health Complete Global Clinical Supply Agreement for Actinium-225 for Targeted Alpha Therapy Pipeline Development

Telix today announces an agreement with Cardinal Health Nuclear & Precision Health Solutions (a subsidiary of Cardinal Health, Inc.) for the global clinical supply of actinium-225 (Ac-225), a therapeutic radioisotope that will be used in developing the Company’s targeted alpha therapy (TAT) pipeline.

Telix Completes Acquisition of QSAM Biosciences and Its Bone Cancer Targeting Platform

Telix today announces the completion of the acquisition of QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer

First Patient Dosed in Austrian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Telix today announces that the first patient has been dosed in its named patient program in Austria for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX (CAIX) targeting positron emission tomography (PET) imaging agent for clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591

Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs in urology at the American Urological Association (AUA) Annual Meeting being held in San Antonio from May 3 – 6 2024.

First Patient Dosed in Special Access Scheme in Australia for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Telix today announces that the first patient has been dosed in a Special Access Scheme (SAS) in Australia for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®) positron emission tomography (PET) imaging in clear cell renal cell carcinoma (ccRCC).